Stryker Corporation
Stryker Reports 2.6% Net Sales Increase in Q1 2026
Summary
Stryker Corporation reported a 2.6% increase in net sales to $6.0 billion for the first quarter of 2026. Organic net sales increased by 2.4%, driven by a 2.1% increase in unit volume and a 0.3% increase in prices. Reported operating income margin was 15.5%, while adjusted operating income margin contracted by 180 basis points to 21.1%. Reported EPS increased by 14.2% to $1.93, while adjusted EPS decreased by 8.5% to $2.60. The company also announced a change in its organizational structure, combining its orthopaedic instruments portfolio with the Mako and enabling technologies portfolio under a new Ortho Tech business. Stryker maintains its full-year 2026 guidance for organic net sales growth in the range of 8.0% to 9.5% and adjusted net earnings per diluted share in the range of $14.90 to $15.10.
Profitelligence Alerts
Get alerts for SYK
Be first to know when Stryker Corporation files with the SEC.
Filing Categories
Advertisement
About Stryker Corporation
Stryker Corporation is a prominent player in the medical technology industry, known for its innovative solutions across healthcare sectors such as orthopedics, medical and surgical, and neurotechnology and spine. The company's purpose is to enhance patient care through its wide array of products, including surgical equipment and advanced medical devices. Stryker plays a critical role in the healthcare market by providing essential tools and technologies that assist in improving surgical precision and patient recovery processes. With a continuous focus on research and development, Stryker Corporation remains at the forefront of medical advancements, directly impacting hospitals, surgical centers, and healthcare providers globally. The company's extensive distribution network and partnerships with medical professionals ensure that its technologies contribute to improving health outcomes across diverse geographical regions.
Official SEC Documents
Advertisement